Chemotherapy in the elderly

European Journal of Surgical Oncology

Volumn 24, Issue 5, 1998, Pages 412-417

  Wilking, N ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chemotherapy; Elderly patients

Indexed keywords

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; GERIATRIC CARE; HEARING; HEART FUNCTION; HUMAN; KIDNEY FUNCTION; LIFE EXPECTANCY; MOBILIZATION; PRIORITY JOURNAL; SOCIAL ASPECT; SOCIOECONOMICS; VISION;

EID: 0031724070     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(98)92217-X     Document Type: Article

References (44)

1. Monfardini S, Chabner B. Joint NCI/EORTC Consensus Meeting on neoplasia in the elderly. Eur J Cancer 1991; 27: 653-4.
2. Fentiman IS. Are the elderly receiving appropriate treatment for cancer? Ann Oncol 1996; 7: 657-8.
3. De Rijke JM, Schouten LJ, Schouten HC, et al. Age-specific differences in the diagnosis and treatment of cancer patients aged 50 years and older in the province of Limburg, the Netherlands. Ann Oncol 1996; 7: 677-85.
4. Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst 1994; 86: 1766-70.
5. Trimble EL, Carter CL, Carin D, et al. Representation of older patients in cancer treatment trials. Cancer 1994; 74: 2208-14.
6. Fried LP, Storer DJ, King DE, et al. Diagnosis of illness presentation in the elderly. J Am Geratr Soc 1991; 39: 117-23.
7. Satariano WA, Ragland DA. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994; 120: 104-10.
8. Externmann M, Balducci L. Issues of clinical research in older persons with cancer. In: Balducci L, Lyman GH, Ershler WB (eds) Comprehensive Geriatric Oncology. New York: Harwood Academic, 1998.
9. Desch CE, Hilner BE, Smith TJ, Retchin SM. Should elderly receive chemotherapy for node-negative breast cancer? A cost effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol 1993; 11: 777-82.
10. Caranasos GJ. A more opportune description of stages of aging. J Am Geriair Soc 1993; 41: 886-90.
11. Eliopoulos C. Gerontological Nursing. 4th edn. Philadelphia: JB Lippincott, 1997.
12. Manton KG, Stallard E. Cross-sectional estimates of active life expectancy for the US elderly and oldest-old population. J Geront 1991; 46: 170-82.
13. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 1983; 52: 1986-92.
14. McKenna RJ. Clinical aspects of cancer in the elderly. Cancer 1994; 74: 2107-17.
15. Balducci L, Mowry K. Pharmacology and organ toxicity of chemotherapy in older patients. Oncology 1992; 6: 62-8.
16. Greenblatt DJ. Elimination half-life of drugs: value and limitations. Ann Rev Med 1985; 36: 421-7.
17. Balducci L, Parker M, Sexton W. et al. Pharmacology of antineoplastic agents in the elderly. Semin Oncol 1989; 16: 76-84.
18. Balducci L, Phillips DM, Wallace C, Hardy C. Cancer chemotherapy in the elderly. Am Fam Physician 1987; 35: 133-43.
19. Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriair Soc 1984; 32: 269-73.
20. Baranovsky A, Myears MH. Cancer incidence and survival in patients 65 years of age and older. Cancer 1986; 36: 26-41.
21. Crivellari D, Bonetti M, Castiglione M. Adjuvant treatment of elderly patients with node-positive breast cancer: CMF tolerability in International Breast Cancer Study Group trial VII. American Society of Clinical Oncology 1998, abstract 394.
22. Silverberg E, Boring CC, Squires TS. Cancer statistics, 1990. CA 1990; 40: 9-26.
23. Heriot AG, Kumar D. Adjuvant therapy for resectable rectal and colonic cancer. Br J Surg 1998; 85: 300-9.
24. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336: 980-7.
25. Ross PJ, Popscu RA, Cunningham D, et al. Adjuvant and palliative chemotherapy for colorectal cancer patients aged 70 years and older. American Society of Clinical Oncology 1998, abstract 1069.
26. Goldberg RM, Kugler J, Sargent DJ, Mahoney MR. A phase II trial of a seven day regimen of oral 5-fluorouracil in untreated patients with metastatic colorectal cancer: a North Central Cancer Treatment Group Study. American Society of Clinical Oncology 1998, abstract 1084.
27. Thatcher N, Anderson H, Betticher DC, et al. Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer. Anti-Cancer Drugs 1995; 6 (Suppl. 6): 39-48.
28. Sternberg CN, Yagoda A, Scher HI. Methotrexate, vinblastine, doxorubicin and cisplatin for advanced transitional cell carcimona of the urothelium. Cancer 1989; 64: 2448-58.
29. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomised trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8: 1050-55.
30. Harrison JD, Fielding JWL. Prognostic factors for gastric cancer influencing clinical practice. World J Surg 1995; 19: 496-500.
31. Kurihara M, Koizumi W, Hasegawa K, et al. Late phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with advanced gastric cancer. American Society of Clinical Oncology 1998, abstract 1007.
32. Seymour MT, Dent JT, Papamichael D, et al. Epirubicin, cisplatin and oral UFT: an active and convenient regimen in upper gastrointestinal cancer. American Society of Clinical Oncology 1998, abstract 996.
33. Dixon DO, Neilan B, Jones S, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma. The Southwest Oncology Group experience. J Clin Oncol 1986; 4: 295-305.
34. Sola-Celigny P, Chastang C, Herrera A, et al. Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma. Am J Med 1987; 83: 1075-9.
35. Shipp MA. Prognistic factors in aggressive non-Hodgkin's lymphoma. Who has "high risk" disease? Blood 1994; 83: 1165-73.
36. Repetto L, Vercelli M, Simoni C, et at. Comorbidity among elderly patients with and without cancer. American Society of Clinical Oncology 1994, abstract 467a.
37. Feldman EJ. Acute myelogenous leukemia in older patients. Semin Oncol 1995; 22: 21-4.
38. Casper ES, Green MR, Brown DP, et al. Phase II trial of gemcitabine in patients with pancreatic cancer. American Society of Clinical Oncology 1991, abstract 440.
39. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine in previously platinum treated ovarian cancer patients. An update. American Society of Clinical Oncology 1993, abstract 262.
40. Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994; 5/2: 182-4.
41. Benjamin RS. Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin Oncol 1995; 22: 11-3.
42. Muss HB. The role of chemotherapy and adjuvant therapy in the management of breast cancer in older women. Cancer 1994; 74: 2165-71.
43. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997; 8: 837-55.
44. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metatstatic colorectal cancer. J Clin Oncol 1996; 14: 709-15.